Data presented today at The International Liver Congress™ 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management ...

Much of the focus on diabetes complications centers on cardiovascular disease and chronic kidney disease, but a fast-emerging area of inquiry is the association of diabetes with liver ...

Ozempic is well-known for its ability to manage type 2 diabetes and aid weight loss. . But as more research emerges, additional health benefits of the GLP-1 drug are being uncovered. Previous studies ...

- Achieved Up to 40% Mean Reduction in Liver Fat in PNPLA3 I148M Homozygotes After Single-Dose After a single dose in a Phase 1 clinical study, ARO-PNPLA3 achieved encouraging results, including: A ...

For those dealing with fatty liver disease, there’s welcome news to report. Earlier this year, the United States Food and Drug Administration (FDA) approved the first and only fatty liver disease drug ...

GLP-1RAs and SGL2 inhibitors were associated with lower risks for NAFLD and NASH among patients with type 2 diabetes. Newer classes of glucose-lowering agents may reduce risk for liver disease among ...

Between 2010 and 2021, India recorded a 13.2 percent increase in non-alcoholic fatty liver disease (NAFLD) cases. According ...

What is fatty liver disease? The most common liver disorder in the United States, nonalcoholic fatty liver disease (NAFLD) is an accumulation of excess fat in liver cells, taking up 5 to 10 percent of ...